Sutro Biopharma (STRO) EBIT (2017 - 2026)
Sutro Biopharma (STRO) posted EBIT of -$38.0 million for Q4 2025, up 21.48% sequentially from -$48.5 million in Q3 2025, and up 41.69% YoY from -$26.9 million in Q4 2024.
Sutro Biopharma (STRO) EBIT (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported EBIT for 9 years, with the latest figure at -$38.0 million in Q4 2025.
- Quarterly EBIT rose 41.69% year-over-year to -$38.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$158.4 million (up 33.59% YoY) and the FY2025 annual result came in at -$158.4 million, up 33.59% from the prior year.
- EBIT advanced to -$38.0 million in Q4 2025 per STRO's latest filing, from -$48.5 million in the prior quarter.
- Over five years, EBIT peaked at $43.2 million in Q4 2023 and troughed at -$68.5 million in Q1 2025.
- A 5-year average of -$35.7 million and a median of -$40.7 million in 2022 frame the typical range for EBIT.
- The sharpest annual moves came in 2023 and 2024: EBIT surged 187.67% in 2023, then sank 251.23% in 2024.
- Over 5 years, EBIT stood at -$35.0 million in 2021, then tumbled by 40.49% to -$49.2 million in 2022, then soared by 187.67% to $43.2 million in 2023, then tumbled by 251.23% to -$65.3 million in 2024, then surged by 41.69% to -$38.0 million in 2025.
- According to Business Quant data, EBIT over the past three periods registered -$38.0 million, -$48.5 million, and -$3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | -29.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.89 Mn |
| Dec 31, 2025 | -38.05 Mn |
| Sep 30, 2025 | -48.46 Mn |
| Jun 30, 2025 | -3.35 Mn |
| Mar 31, 2025 | -68.51 Mn |
| Dec 31, 2024 | -65.26 Mn |
| Sep 30, 2024 | -67.92 Mn |
| Jun 30, 2024 | -48.69 Mn |
| Mar 31, 2024 | -56.59 Mn |
| Dec 31, 2023 | 43.15 Mn |
| Sep 30, 2023 | -44.01 Mn |
| Jun 30, 2023 | -46.18 Mn |
| Mar 31, 2023 | -42.24 Mn |
| Dec 31, 2022 | -49.22 Mn |
| Sep 30, 2022 | -21.21 Mn |
| Jun 30, 2022 | -19.38 Mn |
| Mar 31, 2022 | -39.13 Mn |
| Dec 31, 2021 | -35.04 Mn |
| Sep 30, 2021 | -34.67 Mn |
| Jun 30, 2021 | -9.81 Mn |